PPARG and metabolic dysfunction-associated steatotic liver disease: Despite the current lack of trials addressing the efficacy of fibrates in patients with partial lipodystrophy, our results raise concerns regarding the potential value of fibrates for the management of hypertriglyceridaemia/NAFLD in carriers of the dominant negative P467L‐PPARγ mutation.